CALB2 Overexpression Attenuates Neuropathic Pain by Inhibiting Oxidative Stress and Modulating Microglia M1/M2

Junxiu Jin1, Xiang Xu2, Xiaoling Xu2

  • 1Department of Anesthesia, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Neurochemical Research
|October 23, 2025
PubMed

Insights

Calbindin-2 (CALB2) gene therapy shows promise for treating neuropathic pain (NP). Overexpressing CALB2 reduces inflammation and oxidative stress, alleviating NP symptoms in rats by activating the cAMP/CREB pathway.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Neuropathic pain (NP) is a debilitating chronic condition with limited effective treatments.
  • Understanding the molecular mechanisms underlying NP is crucial for developing novel therapies.

Purpose of the Study:

  • To investigate the role of calbindin-2 (CALB2) in neuropathic pain.
  • To explore the therapeutic potential of CALB2 in alleviating NP symptoms.

Main Methods:

  • Bioinformatic analysis of gene expression datasets (GSE2636, GSE24982).
  • Establishment of a rat spinal nerve ligation (SNL) model and a lipopolysaccharide (LPS)-induced BV2 cell model.
  • Assessment of CALB2 function through overexpression studies in vitro and in vivo.

Main Results:

  • CALB2 was identified as a key gene downregulated in NP models.
  • CALB2 overexpression in BV2 cells reduced apoptosis, inhibited M1 microglia polarization, and decreased oxidative stress markers.
  • CALB2 overexpression in SNL rats improved pain thresholds and latencies.
  • CALB2 exerts its effects by activating the cAMP/CREB signaling pathway.

Conclusions:

  • CALB2 plays a significant role in the pathogenesis of neuropathic pain.
  • CALB2 overexpression demonstrates therapeutic potential for NP by modulating microglia activation, reducing oxidative stress, and activating the cAMP/CREB pathway.
  • Targeting CALB2 represents a promising strategy for NP treatment.